Clinical Trial Update: PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer [NA]

View source ↗

Summary

A clinical trial update indicates a study evaluating trastuzumab deruxtecan using PERCIST criteria for HER2-low metastatic breast cancer, which is not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low-expressing Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Centre Paul Strauss | Conditions: Metastatic Breast Cancer, HER 2 Low-expressing Breast Cancer | NA | Status: NOT_YET_RECRUITING